Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone434-422-9800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees3
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions
What is Adial Pharmaceuticals' stock symbol?
Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."
When is Adial Pharmaceuticals' next earnings date?
What price target have analysts set for ADIL?
2 analysts have issued 12 month price objectives for Adial Pharmaceuticals' shares. Their predictions range from $5.00 to $5.00. On average, they expect Adial Pharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 235.7% from the stock's current price. View Analyst Price Targets for Adial Pharmaceuticals.
What is the consensus analysts' recommendation for Adial Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adial Pharmaceuticals.
What are Wall Street analysts saying about Adial Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adial Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE. " (6/11/2019)
- 2. Maxim Group analysts commented, "Adial announced that the company is expanding its activities around its lead asset AD04, beyond alcohol use disorder (AUD) to now include potential use in patients with opioid use disorder (OUD)." (12/13/2018)
Has Adial Pharmaceuticals been receiving favorable news coverage?
Press coverage about ADIL stock has been trending negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adial Pharmaceuticals earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Adial Pharmaceuticals.
Are investors shorting Adial Pharmaceuticals?
Adial Pharmaceuticals saw a decline in short interest in August. As of August 15th, there was short interest totalling 74,000 shares, a decline of 37.7% from the July 15th total of 118,700 shares. Based on an average daily volume of 47,100 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.1% of the company's shares are sold short. View Adial Pharmaceuticals' Current Options Chain.
Who are some of Adial Pharmaceuticals' key competitors?
Some companies that are related to Adial Pharmaceuticals include Kezar Life Sciences (KZR), SCYNEXIS (SCYX), Jaguar Health (JAGX), Aravive (ARAV), Otonomy (OTIC), Unum Therapeutics (UMRX), Spring Bank Pharmaceuticals (SBPH), ASLAN PHARMACEU/ADR (ASLN), China SXT Pharmaceuticals (SXTC), VERONA PHARMA P/S (VRNA), Ophthotech (OPHT), Hoth Therapeutics (HOTH), Agile Therapeutics (AGRX), Oramed Pharmaceuticals (ORMP) and IMMUTEP LTD/S (IMMP).
What other stocks do shareholders of Adial Pharmaceuticals own?
Who are Adial Pharmaceuticals' key executives?
Adial Pharmaceuticals' management team includes the folowing people:
- Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)
- Prof. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 59)
- Mr. Joseph M. Truluck M.B.A., MBA, CFO & COO (Age 41)
- Ms. Monika Z. Rogozinska, Chief Devel. Officer
- Mr. Alex Lugovoy, Head of Strategy
When did Adial Pharmaceuticals IPO?
(ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.
Who are Adial Pharmaceuticals' major shareholders?
Which major investors are selling Adial Pharmaceuticals stock?
How do I buy shares of Adial Pharmaceuticals?
Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Adial Pharmaceuticals' stock price today?
One share of ADIL stock can currently be purchased for approximately $1.4894.
How big of a company is Adial Pharmaceuticals?
Adial Pharmaceuticals has a market capitalization of $15.25 million. The company earns $-11,630,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Adial Pharmaceuticals employs 3 workers across the globe.View Additional Information About Adial Pharmaceuticals.
What is Adial Pharmaceuticals' official website?
How can I contact Adial Pharmaceuticals?
Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]
MarketBeat Community Rating for Adial Pharmaceuticals (NASDAQ ADIL)
MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
